Vertebral compression fractures and mineral metabolism in chronic obstructive lung disease

J A RIACHO, J GONZÁLEZ MACÍAS, C DEL ARCO, J A AMADO, J FREIJANES, M A ANTÓN

From the Departments of Internal Medicine and Pharmacology, Hospital Nacional Marqués de Valdecilla, Facultad de Medicina, Santander, Spain

Abstract  Chronic obstructive lung disease has been reported as a cause of osteoporosis, though whether this association is due to the disease itself or to corticosteroid treatment has not been elucidated. We studied 44 male patients with chronic obstructive lung disease (mean (SD) FEV₁ 39% (14%) of predicted normal) who were not having long term corticosteroids. No differences in a vertebral deformity score or in metacarpal index were found between them and a control group of similar age. Indices of bone formation (serum osteocalcin) and bone resorption (urinary hydroxyproline) were normal and parathyroid hormone and 1,25-dihydroxyvitamin D were also normal. Serum 25-hydroxyvitamin D was decreased, indicating depleted vitamin D. Calcitonin concentrations were higher in the patient than in the control group of the same age. There was no increase in the prevalence of osteoporosis in patients with chronic obstructive lung disease who had not received long term corticosteroid treatment. Increased concentrations of calcitonin may protect the skeleton from the detrimental effect of hypovitaminosis D.

Osteoporosis has been reported in patients with chronic obstructive lung disease, but this association is not well established. Most studies, however, have been performed in asthmatic patients rather than in patients with chronic obstructive bronchitis or emphysema, and have usually focused on the influence of corticosteroid administration, an accepted factor in the pathogenesis of osteoporosis. Other factors present in patients with chronic obstructive lung disease may be risk factors for osteoporosis. Important among them may be: low levels of physical activity, low sunlight exposure, a history of smoking, a history of alcohol consumption (which is known to be increased in chronic obstructive lung disease), and administration of calciretic agents such as frusemide. Whether patients with chronic obstructive lung disease develop osteoporosis in the absence of steroid treatment is not known. Recent studies in asthmatic patients found a decreased bone mass only in patients treated with corticosteroids, contradicting some older reports.

This study was undertaken to determine whether the prevalence of osteoporosis was increased in men with chronic obstructive lung disease who had not had long term corticosteroid treatment and to study the activity of hormonal systems regulating bone metabolism in those patients.

Methods

Subjects
A prospective study was performed from December 1983 to September 1985. Entry criteria were a firm clinical and spirometric diagnosis of chronic obstructive lung disease and the ability to cooperate with the study. Patients with neoplasia, diabetes mellitus, liver disease (apart from liver congestion due to cor pulmonale), or impaired renal function were excluded. By definition, patients with a history of chronic corticosteroid treatment were also excluded. Chronic corticosteroid administration was defined as daily or alternate day administration for one year or more, or more than seven short courses of high dose treatment a year. The study population consisted of 44 men (mean age 65 (SD 9) years). All suffered from symptoms of
their chronic obstructive lung disease, with an FEV1 of less than 80% of the predicted value. Mean (SD) respiratory function values (determined at rest) were: FEV1, 39% (14%), arterial oxygen tension (Pao2) 62 (11) mm Hg (8-3 (1-5) kPa), arterial carbon dioxide tension (Paco2) 47 (8) mm Hg (6-3 (1-1) kPa). Fourteen patients had a Pao2 below 60 mm Hg (8 kPa), and 11 a Paco2, higher than 50 mm Hg (6-7 kPa).

Patients completed a questionnaire that included details of physical activity (average number of kilometres walked each week) and sunlight exposure (number of hours spent outdoors). Details of previous drug treatment and tobacco and alcohol consumption were also obtained. Most patients were taking some combination of theophylline, inhaled salbutamol, and inhaled ipratropium bromide. Seven of them had received short courses of corticosteroids during exacerbations (none more than three courses a year, each lasting no longer than three weeks).

All patients gave informed consent. The study was approved by the hospital research committee.

**Skeletal Radiographic Evaluation**

Lateral radiographs of the thoracic and lumbar spine were evaluated according to published criteria. The anterior, middle, and posterior heights of the vertebral bodies from T3 to L5 were measured. A score reflecting the degree of vertebral deformity due to wedging or compression fracture was determined as follows: (1) The whole spine was given one point. (2) One point was added for every vertebra with a 15–20% reduction in any of its heights, two points for a 21–30% reduction, three for a 31–40% reduction, and four points when the reduction was greater than 40%. Therefore an intact spine had a score of 1, and the higher the score the worse the bone condition.

From radiographs of both hands the medullary width and total width were measured at the midpoint of the 2nd, 3rd, and 4th metacarpal of both hands, and the percentage ratio of cortical area to total area was calculated for each bone. The metacarpal index was taken as the average value of the six measured bones.

The patients’ results were compared with those from a control group composed of 27 subjects of similar age (mean 60 (SD 9) years). All of them had diseases unrelated to bone metabolism, symptoms having been present for less than two months. None had been bedridden. All radiographs were evaluated by one of us (JAR) twice. He made the second reading after an interval of at least three months, being unaware of the score given in the first evaluation. The mean of both measurements was calculated.

**Biochemical Evaluation**

Thirty six of the 44 patients were studied biochemically. Blood samples were obtained for total and ionised calcium, phosphate, creatinine, parathyroid hormone, calcitonin, 25-hydroxyvitamin D (25(OH)D), 1,25-dihydroxyvitamin D (1,25(OH)2D), and osteocalcin (bone-G1a protein). Urine measurements included calcium, phosphate, creatinine, total hydroxyproline, and cyclic AMP (cAMP). Both blood and urine determinations were carried out on several occasions (2–7, mean 3·1) during the study period.

Calcium, creatinine, and phosphate were analysed by standard automatic methods and ionised calcium by a Space-Stat 20 analyser (Orion Biomedical).

Parathyroid hormone was measured by radioimmunoassay (ImmunoNuclear) with a C terminal specific antibody. The normal range is up to 1 ng/ml. Serum calcitonin and osteocalcin were also measured by radioimmunoassay (ImmunoNuclear), the normal ranges being up to 100 pg/ml and 8–6–6 ng/ml respectively. Vitamin D measurements included both D3, and D1 metabolites, and were performed by competitive protein binding assays, after HPLC purification. The normal range for serum 1,25(OH)2D is 18–58 pg/ml (43–139 pmol/l). In normal subjects serum 25(OH)D undergoes profound changes through the year, with a maximum in the late summer (30 (SD 10) ng/ml, 75 (25) nmol/l) and a minimum in late winter (14 (6) ng/ml, 35 (15) nmol/l).

Hydroxyproline and cAMP were measured in a morning two hour urine collection, after a 12 hour fast. Hydroxyproline was analysed by a colorimetric method (Organon Teknika) and the results expressed as the molar ratio to creatinine (normal range 0·005–0·021 mol hydroxyproline/mol creatinine, 5·8–24·4 mg hydroxyproline/g creatinine). cAMP was measured by radioimmunoassay (ImmunoNuclear) and the results were expressed as a function of the glomerular filtration rate (GFR) (normal range 1·85–5·0 nmol/100 mg GFR).

**Statistical Analysis**

The results are expressed as means with standard deviations in parentheses unless otherwise specified. They were compared with those of control groups of similar age distribution. Owing to the difficulty of obtaining radiographs and blood and urine measurements in the same group, different control groups were used for different aspects of the study. The controls for the biochemical studies were all healthy subjects. Mann-Whitney U, Student’s t, and $x^2$ tests and Pearson and Spearman correlation were applied as indicated. A probability of 0·05 was considered significant.

**Results**

**Skeletal Radiographs**

Two subjects in the control group (7·4%) and three in
were observed. No relationship was observed between bone indices and tobacco consumption, alcohol consumption, or sunlight exposure. Patients with a vertebral deformity score higher than 5 walked shorter distances than those with lower score (6 (4) v 16 (10) km/week; p < 0.005). Since no patient complained of back pain, this finding indicates an influence of physical activity on bone.

**BIOCHEMICAL EVALUATION**

Serum total calcium (8.8 (0.5) mg/dl, 2.2 (0.12) mmol/l); ionised calcium (2.27 (0.09) mEq/l, 1.13 (0.04) mmol/l); phosphate (3.4 (0.5) mg/dl, 1.1 (0.1) mmol/l); and TmP/GFR (3.0 (0.8) mg/dl, 1.0 (0.3) mmol/l) were all within the normal range. Mean values of parathyroid hormone, 1,25(OH)2D, osteocalcin, urinary cAMP, and hydroxyproline were also normal.
Vertebral compression fractures and mineral metabolism in chronic obstructive lung disease

(table). Serum calcitonin concentration was significantly higher than in a control group of the same age (table). The patients with chronic obstructive lung disease, however, showed a substantially lower serum 25(OH)D concentration (fig 3), 27% having less than 4.5 ng/ml, the lowest value found among 132 healthy controls. A significant correlation ($r = 0.66$, $p < 0.001$) existed between serum 25(OH)D and the number of hours spent outdoors in the previous two months.

No significant relationship was observed between any of the biochemical indices and radiographic bone indices. Likewise, patients with vitamin D deficiency (serum 25(OH)D below 4.5 ng/ml) had bone indices not significantly different from patients with normal serum 25(OH)D.

Discussion

Chronic obstructive lung disease has been considered to be associated with an increased prevalence of osteoporosis,12 but few studies support this contention. Moreover, the influence of corticosteroid treatment may have been misleading in some of them. Earlier reports suggested an increased incidence of osteoporosis in asthmatic patients independent of corticosteroid treatment.67 Other investigations, however, have not supported this conclusion.3 We have studied a group of unselected men with chronic obstructive lung disease, suffering from chronic obstructive bronchitis or emphysema or both, who were not having chronic corticosteroid treatment. Thus the influence of steroid treatment was avoided in this study. Women were not included because of the much lower incidence of chronic obstructive lung disease in females, and because the menopause would introduce an additional variable in the interpretation of the results.

There was no greater prevalence of vertebral fractures in these patients than in a control group of men matched for age. The low prevalence of vertebral fractures could make it difficult to find differences between the two groups. Nevertheless, our results show that if any difference does exist it must be rather small and probably clinically insignificant. In accordance with that finding no relationship between bone indices and indicators of the severity of lung disease was observed. In addition, urine hydroxyproline and serum osteocalcin, markers for bone resorption and bone formation respectively,13 did not differ between patients and controls, suggesting that bone turnover was normal in the patients under study. Serum concentrations of parathyroid hormone and 1,25(OH)$_2$D, the main hormones regulating mineral metabolism, as well as other indices of parathyroid activity (TmP/GRF, urinary excretion of cAMP), were also normal. Serum calcitonin was significantly increased, in agreement with previous reports.14 This increase has been attributed to an increased synthesis by the Kultschitzky cells of the bronchial epithelium.15 An effect of medications, however, increasing cAMP concentrations in parafollicular cells of the thyroid, cannot be excluded.16

Serum concentrations of 25(OH)D were lower in patients than in controls, a significant proportion of them (27%) having levels below the lower limit of normality. This finding was not explained by decreased concentrations of vitamin D binding protein since the patients had neither protein loosing diseases nor liver insufficiency, and their serum concentrations of albumin were normal. A significant correlation was found between serum 25(OH)D and the time spent outdoors, suggesting that low exposure to sunlight was the reason for the reduced concentrations of 25(OH)D. The hypovitaminosis D reflected by the low serum 25(OH)D concentration has been considered to favour the development of osteoporosis.17 Osteoporosis, however, was not more prevalent in patients than in controls, and no differences in bone indices were found between patients with normal and patients with reduced concentrations of 25(OH)D. Since calcitonin is a physiological inhibitor of bone resorption, it is tempting to speculate that the increased concentrations of serum calcitonin found in these patients could have a protective role, preventing the loss of bone mass.

We found no evidence of an increased prevalence of osteoporosis in patients with chronic obstructive lung disease not having long term corticosteroid treatment, despite the existence of several risk factors for its development.

This work was supported in part by a grant from Caja de Ahorros de Santander y Cantabria.

References

6 Stresemann E, Krokowski E. Der Mineralisationsgrad
Riancho, González Macias, del Arco, Amado, Freijanes, Antón

der Wirbelsäule nach landfristiger Corticosteroid-
behandlung des chronischen Bronchialasthmas. *Klin

7 Krokowski E, Stresemann E. Röntgenologische Bestim-
mungen des Mineralisationsgrades der Wirbelsäule
von Kranken mit chronischem Bronchialasthma. *Klin

8 Kleerekoper M, Parfitt AM, Ellis BL. Measurement of
vertebral fracture rates in osteoporosis. In: Christiansen C, Arnaud CD, Nordin BEC, Parfitt AM, Peck
WA, Riggs BL, eds. *Proceedings of international sym-

9 Nordin BEC. Osteoporosis with particular reference
to the menopause. In: Avioli LV, ed. *The osteoporotic
syndrome: detection, prevention, and treatment*. New

10 Haddad JC, Chyu KJ. Competitive protein-binding
radioassay for 25-dihydroxycholecalciferol. *J Clin
Endocrinol Metab* 1971;33:992–6.

11 Reinhardt TA, Horst RL, Orf JW, Hollis BW. A
microassay for 1,25-dihydroxyvitamin D not requiring
high performance liquid chromatography: application
to clinical studies. *J Clin Endocrinol Metab* 1984;58:
91–4.

12 Goldring SR, Krane SM. Metabolic bone disease:
osteoporosis and osteomalacia. *Disease a Month
1981;27:1–103

13 Brown JP, Delmas PD, Malaval L, Edovard C, Chapuy
MC, Meunier PJ. Serum bone Glα-protein: a specific
marker for bone formation in postmenopausal

14 Galan F, Hurtado J, Perez R, Garrido M. High plasma
calcitonin concentrations in chronic bronchitis. *Br

15 Becker KL, Nash D, Silva OL, Snider RH, Moore CF.
Increased serum and urinary calcitonin levels in

16 Vora NM, Williams GA, Hargis GK, et al. Comparative
effect of calcium and of the adrenergic system on
calcitonin secretion in man. *J Clin Endocrinol Metab

17 Parfitt AM, Gallagher JC, Heaney RP, Johnson CC,
Neer R, Whedon GD. Vitamin D and bone health in the
Vertebral compression fractures and mineral metabolism in chronic obstructive lung disease.

J A Riancho, J González Macías, C Del Arco, J A Amado, J Freijanes and M A Antón

*Thorax* 1987 42: 962-966
doi: 10.1136/thx.42.12.962

Updated information and services can be found at:
[http://thorax.bmj.com/content/42/12/962](http://thorax.bmj.com/content/42/12/962)

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
[http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to:
[http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to:
[http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)